Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Receivables (2016 - 2024)

vTv Therapeutics (VTVT) has disclosed Change in Receivables for 10 consecutive years, with -$180000.0 as the latest value for Q4 2024.

  • Quarterly Change in Receivables fell 276.47% to -$180000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$40000.0 through Dec 2024, up 43.66% year-over-year, with the annual reading at -$40000.0 for FY2024, 43.66% up from the prior year.
  • Change in Receivables hit -$180000.0 in Q4 2024 for vTv Therapeutics, down from -$64000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $928000.0 in Q3 2021 to a low of -$871000.0 in Q4 2021.
  • Historically, Change in Receivables has averaged $4133.3 across 5 years, with a median of -$2000.0 in 2021.
  • Biggest YoY gain for Change in Receivables was 6528.57% in 2021; the steepest drop was 704.86% in 2021.
  • Year by year, Change in Receivables stood at $144000.0 in 2020, then plummeted by 704.86% to -$871000.0 in 2021, then surged by 113.32% to $116000.0 in 2022, then dropped by 12.07% to $102000.0 in 2023, then crashed by 276.47% to -$180000.0 in 2024.
  • Business Quant data shows Change in Receivables for VTVT at -$180000.0 in Q4 2024, -$64000.0 in Q3 2024, and -$675000.0 in Q2 2024.